Last reviewed · How we verify
Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations
Approved treatments
- Pf-06804103 · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations patent landscape — cliff calendar, originator estates, attackable patents
- Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations treatment landscape brief
- Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations treatment updates RSS
Frequently asked questions about Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations
What drugs treat Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations?
Tracked treatments include Pf-06804103.
What is the treatment for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations?
Standard treatment for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations includes Pf-06804103. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations patent cliff · Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations CI report
- Treatment: Pf-06804103 · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing